Exeliom Biosciences
PrivateLast Round
Series A
Extension
Oct 21, 2025
Total Funding Raised
$28.98M
Company Overview
Exeliom Biosciences is a biotechnology company that develops microbiome-based immunotherapies using single bacterial strain drug candidates to treat inflammatory bowel diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exeliom Biosciences Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Exeliom Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 21, 2025 | ||||
| Grant | Mar 6, 2024 | ||||
| Grant | Nov 28, 2023 | ||||
| Series A Extension | Jul 3, 2023 | ||||
| Grant | Aug 3, 2020 | ||||
Grant | Aug 12, 2019 |
Key People
Founding team and executive leadership
Exeliom Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forepont Capital Partners | Series A Extension |
| CE-Ventures | Series A Extension |
| Bpifrance | Grant, Series A |
| Sofimac Innovation | Series A |
| National Research Institute for Agriculture, Food and Environment | Series A |
| Auriga Partners | Series A Extension, Series A |
| Capital Grand Est | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 10, 2025
Announced the launch of LIVEDIFF Part 2.
- Jun 30, 2023
$26M round completed.
Exeliom Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Exeliom Biosciences's valuation, stock price, and market status.